Author

Alexis I. Cocozaki

Observed names: A. Cocozaki, A. I. Cocozaki, A.I. Cocozaki, Alexis Cocozaki, Alexis I. Cocozaki, Cocozaki, A.

Observed institutions: Florida State University, University of Balamand, Epizyme (United States), Ipsen (United States), AstraZeneca (United States), American University of Beirut

ORCID: 0000-0002-3547-552X

Observed ORCID: 0000-0002-3547-552X

OpenAlex ID: A5058456108

Structure of an RNA Silencing Complex of the CRISPR-Cas Immune System

2013 · Michael Spilman, Alexis Cocozaki, et al. · Molecular Cell · 136

Target RNA capture and cleavage by the Cmr type III-B CRISPR–Cas effector complex

2014 · Caryn R. Hale, Alexis Cocozaki, et al. · Genes & Development · 113

PDF

Structure of the Cmr2 Subunit of the CRISPR-Cas RNA Silencing Complex

2012 · Alexis I. Cocozaki, Nancy F. Ramia, et al. · Structure · 77

PDF

Essential Structural and Functional Roles of the Cmr4 Subunit in RNA Cleavage by the Cmr CRISPR-Cas Complex

2014 · Nancy F. Ramia, Michael Spilman, et al. · Cell Reports · 61

PDF

Resistance mutations generate divergent antibiotic susceptibility profiles against translation inhibitors

2016 · Alexis I. Cocozaki, Roger B. Altman, et al. · Proceedings of the National Academy of Sciences · 53

PDF

Structure of the Cmr2-Cmr3 Subcomplex of the Cmr RNA Silencing Complex

2013 · Yaming Shao, Alexis I. Cocozaki, et al. · Structure · 49

PDF

Staphylococcus epidermidis Csm1 is a 3'-5' exonuclease

2013 · N. F. Ramia, L. Tang, et al. · Nucleic Acids Research · 37

PDF

Structural Insights Lead to a Negamycin Analogue with Improved Antimicrobial Activity against Gram-Negative Pathogens

2015 · David C. McKinney, Gregory S. Basarab, et al. · ACS Medicinal Chemistry Letters · 16

Bacteriophage P22 Antitermination boxB Sequence Requirements Are Complex and Overlap with Those of λ

2008 · Alexis I. Cocozaki, Ingrid R. Ghattas, et al. · Journal of Bacteriology · 13

Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation

2024 · Lily L. Nguyen, Zachary L. Watson, et al. · Molecular Cancer Therapeutics · 12

PDF

Antimicrobial susceptibility patterns of Haemophilus influenzae and Streptococcus pneumoniae isolates in a Beirut general university hospital between 2000 and 2004

2006 · Z. Daoud, A. Cocozaki, et al. · Clinical Microbiology and Infection · 9

PDF

The RNA-Binding Domain of Bacteriophage P22 N Protein Is Highly Mutable, and a Single Mutation Relaxes Specificity toward λ

2008 · Alexis I. Cocozaki, Ingrid R. Ghattas, et al. · Journal of Bacteriology · 8

Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma

2026 · Elena Adan-Villaescusa, Borja Castello-Uribe, et al. · Cell Reports Medicine · 7

Reawakening of Human Fetal Hemoglobin and an Epigenetic Path to the Clinic for Sickle Cell Disease and Beta-Thalassemia: Identification of an Orally-Available, Potent, and Selective Euchromatic Histone Lysine Methyltransferase 1 and 2 (EHMT1/2) Inhibitor

2017 · Elayne Chan-Penebre, Veronica Gibaja, et al. · Blood · 4

Supplementary Table S1 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation

2024 · Lily L. Nguyen, Zachary L. Watson, et al. · 2

Supplementary Figure S1 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation

2024 · Lily L. Nguyen, Zachary L. Watson, et al. · 1

Supplementary Legends from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation

2024 · Lily L. Nguyen, Zachary L. Watson, et al. · 1

Supplementary Figure S3 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation